Braftovi plus Erbitux and FOLFIRI showed significant ORR benefits in BRAF V600E–mutant mCRC compared to the control regimen. The combination therapy achieved a confirmed ORR of 64.4% versus 39.2% with ...
Investor's Business Daily on MSN
How S&P 500 giant Pfizer is tackling hard-to-treat cancers
Pfizer said Sunday its Braftovi-tied regimen nearly doubled the length of time colon cancer patients lived without getting sicker.
REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer—Response ...
Awareness and penetration of KRAS mutation testing in the treatment of patients with metastatic colorectal cancer. Background: Bevacizumab (BV) has been demonstrated to improve survival outcome in ...
Yakult Honsha has patented a method for predicting the effectiveness of FOLFOX or FOLFIRI regimens in treating stage IV colorectal cancer. By measuring copy number gains in specific chromosome regions ...
Combining chemotherapy with one or two immune checkpoint inhibitors (ICIs) as second-line treatment for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma failed to improve progression ...
LUGANO, 20 November 2017 - A randomised trial in 650 patients has confirmed the safety and efficacy of a new second line treatment for metastatic colorectal cancer, researchers report at the ESMO Asia ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline progression-free (PFS) survival results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results